Evidence map›Paper›PMID 35117912›Full record

ArticleTranslational cancer research2020

Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells.

Amin Li, Weiya Cao, Xueke Liu, Yinci Zhang, Yongfang Ma, Ruyue Xu, Xiaolong Tang

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amin Li *Medical School, Anhui University of Science & Technology, Huainan, China.
Weiya Cao *Medical School, Anhui University of Science & Technology, Huainan, China.
Xueke Liu *Medical School, Anhui University of Science & Technology, Huainan, China.
Yinci Zhang *Medical School, Anhui University of Science & Technology, Huainan, China.
Yongfang MaMedical School, Anhui University of Science & Technology, Huainan, China.
Ruyue XuMedical School, Anhui University of Science & Technology, Huainan, China.
Xiaolong TangMedical School, Anhui University of Science & Technology, Huainan, China.
Anhui University of Science and Technology · CNHuaian First People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGefitinib is a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has become first-line treatment for patients with mutant EGFR non-small cell lung cancer (NSCLC). Despite its anti-tumor activity, the benefit of gefitinib in patients with wild-type EGFR NSCLC is debated. This work aimed to evaluate the effects of gefitinib on cisplatin-resistant wild-type EGFR NSCLC cells in

methodsWe established a cisplatin-resistant wild-type EGFR NSCLC cell line, H358

resultsEGFR and the downstream node molecules ERK and AKT were significantly more phosphorylated in H358

conclusionsAbnormal activation of EGFR in H358

Indexed as

cisplatinepidermal growth factor receptor (EGFR)Gefitinibnon-small cell lung cancer (NSCLC)wild-type EGFR

Identifiers

PMID35117912
PMCPMC8798197
OpenAlexW3082279540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.